Sorriso Pharmaceuticals develops novel oral antibodies designed to treat immune-mediated diseases. The company focuses on creating therapeutic options that address current unmet medical needs within this patient population. Their pipeline centers on advancing these unique antibody therapies through clinical development.
Funding
$31M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antibody therapies for inflammatory diseases often require intravenous administration, which can be inconvenient and costly for patients. These traditional therapies may also lead to systemic immunosuppression, increasing the risk of side effects. There is a need for more targeted and patient-friendly treatment options that can deliver antibodies directly to the site of inflammation in the gut.
Solution
Sorriso Pharmaceuticals is developing a pipeline of novel, orally administered antibodies, called Vorabodies, designed to address unmet needs in immune-mediated diseases such as ulcerative colitis and Crohn's disease. The platform generates potent antibodies that maintain activity throughout the human intestine, allowing for targeted delivery to the inflamed tissue. The lead candidate, SOR102, is being developed for inflammatory bowel disease (IBD) and simultaneously inhibits TNF⍺ and IL-23(p19), two clinically validated drivers of IBD, providing combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. This oral delivery approach offers a more convenient and potentially safer alternative to traditional injectable antibody therapies.
Target Audience
The primary target audience includes patients with immune-mediated diseases, particularly inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn's disease, as well as physicians specializing in gastroenterology and immunology.
Features
- Orally administered antibodies (Vorabodies) for targeted delivery to the gut
- Antibody engineering platform designed to maintain activity throughout the intestine
- Lead candidate (SOR102) targeting TNF⍺ and IL-23(p19) for IBD treatment
- Gut-restricted treatment approach to manage ICI mediated colitis (IMC)
- Potential for reduced systemic immunosuppression compared to traditional therapies
- Pipeline of disease-modifying antibodies for various immune-mediated diseases